Lead Product(s): Ifx-1
Therapeutic Area: Dermatology
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2020
Two out of the first five patients dosed with IFX-1 achieved complete remission. Dose escalation warranted by pharmacodynamic analysis and approved by relevant authorities in 3 dose cohorts.